Human gastrointestinal tumor, prostate and ovary carcinomas.
This product was changed from ascites to tissue culture supernatant on 15th June 2017. Lot numbers higher than GR225970-2 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: Ready to use.
IHC-Fr: Ready to use.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase: ST6GalNAc I, which catalyzes the transfer of a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. The resulting disaccharide (Neu5Acalpha2-6GalNAcalpha1-O-Ser/Thr) cannot be further elongated and sialyl-Tn expression results therefore in a shortening of the O-glycan chains